TDMS Study 05122-06 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
NICKEL SULFATE HEXAHYDRATE
NTP Experiment-Test: 05122-06 Report: PEIRPT05
Study Type: CHRONIC Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 03:47:06
Facility: Lovelace Inhalation Toxicology Research Institute
Chemical CAS #: 010101970
Lock Date: 04/19/94
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05122-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NICKEL SULFATE HEXAHYDRATE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 03:47:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0.0 0.0MG/M3 0.25 .25MG/M3 0.5 0.5MG/M3
MG/M3 LUNG TOX MG/M3 LUNG TOX MG/M3 LUNG TOX
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 20 60 20 60 20
Scheduled Sacrifice 19 20 20
Early Deaths
Moribund Sacrifice 19 1 11 11
Natural Death 7 10 4
Survivors
Moribund Sacrifice 1 1
Terminal Sacrifice 33 38 45
Animals Examined Microscopically 60 11 60 10 60 10
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (59) (6) (55) (5) (57) (5)
Wall, Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Intestine Large, Colon (60) (6) (57) (5) (58) (5)
Intestine Large, Rectum (56) (4) (57) (4) (55) (4)
Anus, Squamous Cell Papilloma 1 (2%)
Intestine Large, Cecum (60) (6) (57) (5) (60) (5)
Lymphatic, Cholangiocarcinoma, Metastatic,
Liver 1 (2%)
Intestine Small, Duodenum (57) (6) (57) (5) (59) (5)
Adenocarcinoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Serosa, Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Intestine Small, Jejunum (60) (6) (58) (5) (59) (5)
Histiocytic Sarcoma 1 (2%)
Intestine Small, Ileum (60) (6) (58) (5) (58) (5)
Liver (60) (6) (59) (5) (60) (5)
Cholangiocarcinoma 1 (2%)
Hepatocellular Carcinoma 7 (12%) 9 (15%) 5 (8%)
Hepatocellular Carcinoma, Multiple 5 (8%)
Hepatocellular Adenoma 11 (18%) 13 (22%) 10 (17%) 2 (40%)
Hepatocellular Adenoma, Multiple 2 (3%) 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 2 (3%) 2 (3%)
Pheochromocytoma Malignant, Metastatic,
Adrenal Medulla 1 (2%)
Mesentery (7) (4) (4)
Carcinoma, Metastatic, Lung 1 (25%)
Cholangiocarcinoma, Metastatic, Liver 1 (25%)
Fibrosarcoma, Metastatic, Skin 1 (14%)
Histiocytic Sarcoma 1 (14%) 1 (25%)
Pancreas (59) (6) (58) (5) (60) (5)
Page 2
NTP Experiment-Test: 05122-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NICKEL SULFATE HEXAHYDRATE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 03:47:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0.0 0.0MG/M3 0.25 .25MG/M3 0.5 0.5MG/M3
MG/M3 LUNG TOX MG/M3 LUNG TOX MG/M3 LUNG TOX
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Salivary Glands (60) (6) (59) (5) (60) (5)
Stomach, Forestomach (60) (6) (58) (5) (60) (5)
Histiocytic Sarcoma 1 (2%)
Squamous Cell Papilloma 1 (2%)
Serosa, Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Stomach, Glandular (59) (6) (58) (5) (59) (5)
Carcinoma, Metastatic, Lung 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (60) (6) (59) (5) (60) (5)
Carcinoma, Metastatic, Lung 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Neoplasm NOS, Metastatic, Uncertain Primary
Site 1 (2%)
Epicardium, Cholangiocarcinoma, Metastatic,
Liver 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (59) (6) (58) (5) (60) (5)
Capsule, Adenoma 1 (2%)
Extra Adrenal Tissue, Carcinoma, Metastatic,
Lung 1 (2%)
Extra Adrenal Tissue, Cholangiocarcinoma,
Metastatic, Liver 1 (2%)
Extra Adrenal Tissue, Histiocytic Sarcoma 1 (2%)
Adrenal Medulla (59) (6) (57) (5) (60) (5)
Pheochromocytoma Malignant 1 (2%)
Pheochromocytoma Benign 1 (2%) 1 (2%)
Islets, Pancreatic (59) (6) (56) (5) (59) (5)
Adenoma 2 (3%) 1 (2%) 1 (2%)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Parathyroid Gland (40) (4) (44) (3) (50) (5)
Pituitary Gland (58) (6) (56) (5) (59) (5)
Pars Distalis, Adenoma 8 (14%) 9 (16%) 5 (8%)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (59) (6) (59) (5) (60) (5)
Follicular Cell, Adenoma 1 (2%) 2 (3%)
Follicular Cell, Adenoma, Multiple 1 (2%)
____________________________________________________________________________________________________________________________________
Page 3
NTP Experiment-Test: 05122-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NICKEL SULFATE HEXAHYDRATE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 03:47:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0.0 0.0MG/M3 0.25 .25MG/M3 0.5 0.5MG/M3
MG/M3 LUNG TOX MG/M3 LUNG TOX MG/M3 LUNG TOX
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (5) (8) (4)
Fibrosarcoma, Metastatic, Skin 1 (25%)
Mediastinum, Carcinoma, Metastatic, Lung 1 (25%)
Mediastinum, Cholangiocarcinoma, Metastatic,
Liver 1 (13%)
Mediastinum, Fibrosarcoma, Metastatic, Skin 1 (20%)
Thoracic, Carcinoma, Metastatic, Lung 1 (25%)
Thoracic, Neoplasm NOS, Metastatic,
Uncertain Primary Site 1 (13%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (58) (6) (58) (5) (60) (5)
Cystadenoma 2 (3%) 1 (2%)
Granulosa Cell Tumor Malignant 1 (2%)
Granulosa Cell Tumor Benign 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Luteoma 1 (20%)
Bilateral, Cholangiocarcinoma, Metastatic,
Liver 1 (2%)
Uterus (60) (7) (60) (7) (60) (6)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Fibroma 1 (2%)
Hemangioma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Leiomyoma 1 (2%)
Leiomyosarcoma 1 (2%)
Polyp Stromal 2 (3%) 2 (3%)
Polyp Stromal, Multiple 1 (2%)
Vagina (1)
Fibroma 1 (100%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (60) (6) (59) (5) (60) (5)
Histiocytic Sarcoma 1 (2%)
Lymph Node (11) (11) (13)
Axillary, Carcinoma, Metastatic, Lung 1 (8%)
Axillary, Fibrosarcoma, Metastatic, Skin 1 (9%)
Iliac, Fibrosarcoma, Metastatic, Skin 1 (9%)
Iliac, Histiocytic Sarcoma 1 (9%) 1 (9%) 1 (8%)
Inguinal, Carcinoma, Metastatic, Lung 1 (8%)
Inguinal, Histiocytic Sarcoma 1 (9%) 1 (9%)
Pancreatic, Carcinoma, Metastatic, Lung 1 (8%)
Page 4
NTP Experiment-Test: 05122-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NICKEL SULFATE HEXAHYDRATE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 03:47:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0.0 0.0MG/M3 0.25 .25MG/M3 0.5 0.5MG/M3
MG/M3 LUNG TOX MG/M3 LUNG TOX MG/M3 LUNG TOX
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Pancreatic, Histiocytic Sarcoma 1 (9%) 1 (8%)
Pancreatic, Neoplasm NOS 1 (8%)
Renal, Histiocytic Sarcoma 1 (9%) 1 (9%) 2 (15%)
Lymph Node, Bronchial (50) (7) (54) (9) (58) (9)
Carcinoma, Metastatic, Lung 1 (2%)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Neoplasm NOS, Metastatic, Uncertain Primary
Site 1 (2%)
Lymph Node, Mandibular (55) (9) (56) (7) (60) (6)
Histiocytic Sarcoma 1 (2%) 2 (3%)
Lymph Node, Mesenteric (56) (6) (52) (3) (56) (5)
Carcinoma, Metastatic, Lung 1 (2%)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 2 (4%)
Lymph Node, Mediastinal (30) (2) (28) (5) (33) (1)
Carcinoma, Metastatic, Lung 1 (3%)
Cholangiocarcinoma, Metastatic, Liver 1 (4%)
Fibrosarcoma, Metastatic, Skin 1 (3%)
Histiocytic Sarcoma 1 (4%) 1 (3%)
Neoplasm NOS, Metastatic, Uncertain Primary
Site 1 (4%)
Spleen (60) (6) (58) (5) (60) (5)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 2 (3%) 1 (2%)
Capsule, Cholangiocarcinoma, Metastatic,
Liver 1 (2%)
Thymus (57) (6) (54) (3) (54) (5)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Histiocytic Sarcoma 1 (2%)
Neoplasm NOS, Metastatic, Uncertain Primary
Site 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (60) (6) (58) (5) (60) (5)
Carcinoma 2 (3%) 1 (2%)
Fibroadenoma 1 (2%)
Skin (60) (6) (59) (5) (59) (5)
Basosquamous Tumor Malignant 1 (2%)
Squamous Cell Papilloma 1 (2%)
Subcutaneous Tissue, Carcinoma, Metastatic,
Lung 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 5 (8%) 1 (2%)
Page 5
NTP Experiment-Test: 05122-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NICKEL SULFATE HEXAHYDRATE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 03:47:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0.0 0.0MG/M3 0.25 .25MG/M3 0.5 0.5MG/M3
MG/M3 LUNG TOX MG/M3 LUNG TOX MG/M3 LUNG TOX
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM - cont
Subcutaneous Tissue, Hemangioma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (60) (6) (60) (5) (60) (5)
Maxilla, Fibrosarcoma, Metastatic, Skin 1 (2%)
Maxilla, Histiocytic Sarcoma 1 (2%)
Skeletal Muscle (4) (3) (3)
Fibrosarcoma, Metastatic, Skin 1 (25%)
Neoplasm NOS, Metastatic, Uncertain Primary
Site 1 (33%)
Abdominal, Carcinoma, Metastatic, Lung 1 (33%)
Abdominal, Cholangiocarcinoma, Metastatic,
Liver 1 (33%)
Diaphragm, Cholangiocarcinoma, Metastatic,
Liver 1 (33%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (60) (6) (59) (5) (59) (5)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (58) (4) (56) (4) (58) (2)
Lung (60) (11) (60) (10) (60) (10)
Alveolar/Bronchiolar Adenoma 3 (5%) 3 (5%) 2 (3%)
Alveolar/Bronchiolar Carcinoma 4 (7%) 3 (5%) 8 (13%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Hepatocellular Carcinoma, Metastatic 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 2 (3%)
Histiocytic Sarcoma 1 (2%)
Neoplasm NOS, Metastatic, Uncertain Primary
Site 1 (2%)
Trachea (60) (6) (60) (5) (60) (5)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (2) (4)
Adenoma 2 (100%) 4 (100%)
Zymbal's Gland (1)
Carcinoma 1 (100%)
Page 6
NTP Experiment-Test: 05122-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NICKEL SULFATE HEXAHYDRATE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 03:47:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0.0 0.0MG/M3 0.25 .25MG/M3 0.5 0.5MG/M3
MG/M3 LUNG TOX MG/M3 LUNG TOX MG/M3 LUNG TOX
____________________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (60) (11) (60) (10) (60) (10)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Histiocytic Sarcoma 1 (2%) 2 (3%)
Perirenal Tissue, Cholangiocarcinoma,
Metastatic, Liver 1 (2%)
Urinary Bladder (59) (5) (60) (5) (58) (5)
Serosa, Cholangiocarcinoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(60) *(11) *(60) *(10) *(60) *(10)
Histiocytic Sarcoma 1 (2%) 4 (7%) 2 (3%)
Lymphoma Malignant 7 (12%) 12 (20%) 9 (15%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 7
NTP Experiment-Test: 05122-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NICKEL SULFATE HEXAHYDRATE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 03:47:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0.0 0.0MG/M3 0.25 .25MG/M3 0.5 0.5MG/M3
MG/M3 LUNG TOX MG/M3 LUNG TOX MG/M3 LUNG TOX
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 41 45 1 40 2
Total Primary Neoplasms 63 78 1 58 2
Total Animals with Benign Neoplasms 27 34 1 22 2
Total Benign Neoplasms 35 41 1 28 2
Total Animals with Malignant Neoplasms 26 27 26
Total Malignant Neoplasms 28 37 29
Total Animals with Metastatic Neoplasms 3 5 2
Total Metastatic Neoplasm 14 33 15
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1
Total Uncertain Neoplasms 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 8
NTP Experiment-Test: 05122-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NICKEL SULFATE HEXAHYDRATE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 03:47:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 1.0 1.0MG/M3
MG/M3 LUNG TOX
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 20
Scheduled Sacrifice 20
Early Deaths
Moribund Sacrifice 17
Natural Death 6
Survivors
Terminal Sacrifice 37
Animals Examined Microscopically 60 10
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Liver (60) (5)
Carcinoma, Metastatic, Lung 1 (2%)
Hemangiosarcoma 1 (2%)
Hepatocellular Carcinoma 10 (17%)
Hepatocellular Carcinoma, Multiple 1 (2%)
Hepatocellular Adenoma 8 (13%) 1 (20%)
Hepatocellular Adenoma, Multiple 1 (2%)
Histiocytic Sarcoma 3 (5%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Mesentery (5)
Fibrosarcoma, Metastatic, Skeletal Muscle 1 (20%)
Histiocytic Sarcoma 1 (20%)
Pancreas (60) (5)
Stomach, Forestomach (60) (6)
Stomach, Glandular (59) (5)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
None
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (60) (5)
Islets, Pancreatic (60) (5)
Adenoma 1 (2%)
Pituitary Gland (57) (4)
Pars Distalis, Adenoma 4 (7%)
Thyroid Gland (60) (5)
Carcinoma, Metastatic, Lung 1 (2%)
Page 9
NTP Experiment-Test: 05122-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NICKEL SULFATE HEXAHYDRATE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 03:47:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 1.0 1.0MG/M3
MG/M3 LUNG TOX
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - cont
Follicular Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (3)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (59) (5)
Granulosa Cell Tumor Benign 1 (2%)
Tubulostromal Adenoma 1 (2%)
Periovarian Tissue, Histiocytic Sarcoma 1 (2%)
Uterus (60) (6)
Histiocytic Sarcoma 2 (3%)
Polyp Stromal 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (60) (5)
Histiocytic Sarcoma 1 (2%)
Lymph Node (13)
Axillary, Histiocytic Sarcoma 1 (8%)
Iliac, Histiocytic Sarcoma 1 (8%)
Pancreatic, Histiocytic Sarcoma 3 (23%)
Renal, Histiocytic Sarcoma 1 (8%)
Lymph Node, Bronchial (56) (8)
Carcinoma, Metastatic, Lung 1 (2%)
Histiocytic Sarcoma 2 (4%)
Neoplasm NOS, Metastatic, Lung 1 (2%)
Lymph Node, Mandibular (55) (6)
Carcinoma, Metastatic 1 (2%)
Histiocytic Sarcoma 2 (4%)
Mast Cell Tumor Benign 1 (2%)
Lymph Node, Mesenteric (51) (4)
Histiocytic Sarcoma 2 (4%)
Lymph Node, Mediastinal (22) (2)
Carcinoma, Metastatic, Lung 1 (5%)
Histiocytic Sarcoma 1 (5%)
Spleen (60) (5)
Histiocytic Sarcoma 1 (2%)
Thymus (56) (5)
Carcinoma, Metastatic, Lung 1 (2%)
Histiocytic Sarcoma 2 (4%)
____________________________________________________________________________________________________________________________________
Page 10
NTP Experiment-Test: 05122-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NICKEL SULFATE HEXAHYDRATE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 03:47:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 1.0 1.0MG/M3
MG/M3 LUNG TOX
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (60) (5)
Carcinoma 1 (2%)
Skin (60) (5)
Subcutaneous Tissue, Fibrosarcoma 2 (3%)
Subcutaneous Tissue, Hemangioma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (60) (5)
Vertebra, Osteosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (56) (4)
Carcinoma, Metastatic, Lung 1 (2%)
Lung (60) (10)
Alveolar/Bronchiolar Carcinoma 1 (2%)
Carcinoma 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Neoplasm NOS 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (1)
Adenoma 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (60) (10)
Carcinoma, Metastatic, Lung 1 (2%)
Histiocytic Sarcoma 1 (2%)
Page 11
NTP Experiment-Test: 05122-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NICKEL SULFATE HEXAHYDRATE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 03:47:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 1.0 1.0MG/M3
MG/M3 LUNG TOX
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(60) *(10)
Histiocytic Sarcoma 4 (7%)
Lymphoma Malignant 6 (10%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 12
NTP Experiment-Test: 05122-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NICKEL SULFATE HEXAHYDRATE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 03:47:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 1.0 1.0MG/M3
MG/M3 LUNG TOX
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 36 2
Total Primary Neoplasms 49 2
Total Animals with Benign Neoplasms 16 2
Total Benign Neoplasms 20 2
Total Animals with Malignant Neoplasms 25
Total Malignant Neoplasms 28
Total Animals with Metastatic Neoplasms 6
Total Metastatic Neoplasm 13
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1
Total Uncertain Neoplasms 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 13
NTP Experiment-Test: 05122-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NICKEL SULFATE HEXAHYDRATE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 03:47:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0.0 0.0MG/M3 0.25 .25MG/M3 0.5 0.5MG/M3
MG/M3 LUNG TOX MG/M3 LUNG TOX MG/M3 LUNG TOX
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 20 60 20 60 20
Scheduled Sacrifice 19 19 18
Early Deaths
Moribund Sacrifice 29 1 29 28 1
Natural Death 5 8 1 8 1
Survivors
Terminal Sacrifice 26 23 24
Animals Examined Microscopically 60 11 60 11 60 12
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (55) (6) (58) (6) (54) (7)
Carcinoma, Metastatic, Liver 1 (2%)
Intestine Large, Colon (59) (6) (60) (6) (58) (7)
Liver (60) (6) (60) (7) (60) (8)
Carcinoma 1 (2%)
Hemangiosarcoma 1 (2%) 2 (3%)
Hepatocellular Carcinoma 10 (17%) 8 (13%) 12 (20%)
Hepatocellular Carcinoma, Multiple 3 (5%) 3 (5%)
Hepatocellular Adenoma 16 (27%) 3 (50%) 6 (10%) 1 (14%) 17 (28%) 2 (25%)
Hepatocellular Adenoma, Multiple 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Mesentery (1) (2) (1)
Carcinoma, Metastatic, Liver 1 (100%)
Histiocytic Sarcoma 1 (50%)
Pancreas (60) (6) (59) (6) (58) (7)
Carcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Salivary Glands (60) (6) (60) (6) (60) (7)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
None
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (60) (6) (59) (6) (59) (7)
Capsule, Adenoma 1 (2%) 1 (2%) 1 (17%) 3 (5%)
Extra Adrenal Tissue, Histiocytic Sarcoma 1 (2%)
Islets, Pancreatic (60) (6) (59) (6) (55) (7)
Page 14
NTP Experiment-Test: 05122-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NICKEL SULFATE HEXAHYDRATE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 03:47:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0.0 0.0MG/M3 0.25 .25MG/M3 0.5 0.5MG/M3
MG/M3 LUNG TOX MG/M3 LUNG TOX MG/M3 LUNG TOX
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - cont
Adenoma 1 (2%)
Thyroid Gland (60) (6) (60) (6) (59) (7)
Follicular Cell, Adenoma 2 (3%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1) (2) (1)
Hemangiosarcoma, Metastatic, Bone 1 (100%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (60) (6) (60) (6) (60) (7)
Carcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%) 2 (3%)
Testes (60) (6) (60) (6) (60) (7)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (60) (6) (60) (6) (59) (7)
Hemangiosarcoma, Metastatic, Bone 1 (2%)
Histiocytic Sarcoma 1 (2%)
Lymph Node (23) (1) (21) (1) (20) (2)
Iliac, Histiocytic Sarcoma 1 (5%)
Pancreatic, Carcinoma, Metastatic, Liver 1 (4%)
Renal, Carcinoma, Metastatic, Liver 1 (4%)
Renal, Histiocytic Sarcoma 1 (5%)
Lymph Node, Bronchial (46) (9) (48) (9) (44) (8)
Carcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Lymph Node, Mandibular (55) (5) (49) (6) (55) (8)
Lymph Node, Mesenteric (55) (5) (53) (5) (55) (5)
Lymph Node, Mediastinal (18) (24) (7) (20)
Spleen (60) (6) (60) (6) (59) (7)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Thymus (54) (5) (48) (6) (51) (7)
____________________________________________________________________________________________________________________________________
Page 15
NTP Experiment-Test: 05122-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NICKEL SULFATE HEXAHYDRATE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 03:47:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0.0 0.0MG/M3 0.25 .25MG/M3 0.5 0.5MG/M3
MG/M3 LUNG TOX MG/M3 LUNG TOX MG/M3 LUNG TOX
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (60) (6) (60) (7) (60) (7)
Subcutaneous Tissue, Mast Cell Tumor NOS 1 (14%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (60) (6) (60) (6) (60) (7)
Hemangiosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (59) (5) (58) (6) (56) (6)
Lung (60) (11) (60) (11) (60) (12)
Alveolar/Bronchiolar Adenoma 3 (5%) 4 (7%) 3 (5%)
Alveolar/Bronchiolar Adenoma, Multiple 2 (3%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 9 (15%) 10 (17%) 3 (5%)
Alveolar/Bronchiolar Carcinoma, Multiple 3 (5%) 1 (2%)
Carcinoma, Metastatic, Liver 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 2 (3%) 3 (5%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (2)
Fibrosarcoma 1 (50%)
Harderian Gland (2) (2)
Adenoma 2 (100%) 2 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (60) (11) (60) (11) (59) (12)
Histiocytic Sarcoma 1 (2%)
Urinary Bladder (59) (6) (59) (6) (58) (7)
Histiocytic Sarcoma 1 (2%)
Page 16
NTP Experiment-Test: 05122-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NICKEL SULFATE HEXAHYDRATE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 03:47:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0.0 0.0MG/M3 0.25 .25MG/M3 0.5 0.5MG/M3
MG/M3 LUNG TOX MG/M3 LUNG TOX MG/M3 LUNG TOX
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(60) *(11) *(60) *(11) *(60) *(12)
Histiocytic Sarcoma 1 (2%) 1 (2%) 2 (3%)
Lymphoma Malignant 2 (3%) 1 (2%) 3 (5%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 17
NTP Experiment-Test: 05122-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NICKEL SULFATE HEXAHYDRATE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 03:47:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0.0 0.0MG/M3 0.25 .25MG/M3 0.5 0.5MG/M3
MG/M3 LUNG TOX MG/M3 LUNG TOX MG/M3 LUNG TOX
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 37 3 35 3 40 2
Total Primary Neoplasms 49 3 44 3 53 2
Total Animals with Benign Neoplasms 21 3 16 2 23 2
Total Benign Neoplasms 23 3 17 2 27 2
Total Animals with Malignant Neoplasms 20 22 25
Total Malignant Neoplasms 26 27 26
Total Animals with Metastatic Neoplasms 3 2 3
Total Metastatic Neoplasm 11 2 3
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1
Total Uncertain Neoplasms 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 18
NTP Experiment-Test: 05122-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NICKEL SULFATE HEXAHYDRATE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 03:47:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 1.0 1.0MG/M3
MG/M3 LUNG TOX
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 20
Scheduled Sacrifice 18
Early Deaths
Moribund Sacrifice 27
Natural Death 8 2
Survivors
Terminal Sacrifice 25
Animals Examined Microscopically 60 12
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Liver (59) (6)
Hepatocellular Carcinoma 8 (14%)
Hepatocellular Carcinoma, Multiple 2 (3%)
Hepatocellular Adenoma 10 (17%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
None
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (59) (6)
Capsule, Adenoma 1 (2%)
Thyroid Gland (60) (7)
Follicular Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
None
____________________________________________________________________________________________________________________________________
Page 19
NTP Experiment-Test: 05122-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NICKEL SULFATE HEXAHYDRATE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 03:47:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 1.0 1.0MG/M3
MG/M3 LUNG TOX
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
None
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
None
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (60) (11)
Alveolar/Bronchiolar Adenoma 4 (7%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%)
Alveolar/Bronchiolar Carcinoma 3 (5%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (3%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (1)
Adenoma 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
None
Page 20
NTP Experiment-Test: 05122-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NICKEL SULFATE HEXAHYDRATE Date: 05/20/95
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 03:47:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 1.0 1.0MG/M3
MG/M3 LUNG TOX
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 27
Total Primary Neoplasms 31
Total Animals with Benign Neoplasms 16
Total Benign Neoplasms 18
Total Animals with Malignant Neoplasms 13
Total Malignant Neoplasms 13
Total Animals with Metastatic Neoplasms 2
Total Metastatic Neoplasm 2
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 21
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------